Neurotrack is transforming the diagnosis of Alzheimer’s disease. Through a safe and non-invasive test, its technology can predict the risk of developing mild cognitive impairment and Alzheimer’s disease years before symptoms occur. Conceived at Emory University and validated by a 5-year study funded by the National Institutes of Health (NIH), it will give pharmaceutical companies better tools to recruit patients for clinical trials, leading to the development of life-saving drugs.

Neurotrack is backed by Founders Fund and Social + Capital, and was the winner of more than $7M in grants from the NIH. It was named Best Health Company at SXSW, DEMO, and participated in the Rock Health accelerator.

Company Growth (employees)
Palo Alto, US
Size (employees)
21 (est)+24%
Neurotrack was founded in 2012 and is headquartered in Palo Alto, US

Neurotrack Office Locations

Neurotrack has an office in Palo Alto

Neurotrack Metrics

Summary Metrics

Founding Date


Total Funding

$9.6 m

Latest funding size

$6.5 m

Time since last funding

about 1 year


Neurotrack's latest funding round in January 2016 was reported to be $6.5 m. In total, Neurotrack has raised $9.6 m

Neurotrack Online Presence

Neurotrack News

Neurotrack Company Life

You may also be interested in